Medicine
Abraxane 100 mg/20 mL powder for injectable suspension
Abraxane 100 mg/20 mL powder for injectable suspension is a prescription medicine containing Paclitaxel for intravenous use, marketed by Abraxis BioScience, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store the vials in original cartons at 20°C to 25°C (68°F to 77°F). Retain in…
Key facts
- Active ingredient (INN)
- Paclitaxel
- Brand
- Abraxane
- Strength
- 100 mg/20 mL
- Dosage form
- Powder for injectable suspension
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- Abraxis BioScience
- Manufacturer
- Abraxis BioScience
- Origin register
- US FDA, United States
- Storage
- Store the vials in original cartons at 20°C to 25°C (68°F to 77°F). Retain in the original package to protect from bright light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01CD01 Paclitaxel
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 10 February 2005
- Identifiers
- RxCUI 583214, 583218DailyMed set ID 24d10449-2936-4cd3-b7db-a7683db721e4NDC 68817-134Application NDA021660
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 20 mL in 1 vial, single-use | 68817-134-50 | Abraxis BioScience | 10 February 2005 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Paclitaxel 100 mg/20 mL powder for injectable suspension.
- Paclitaxel 100 mg/20 mL powder for injectable suspensionAvailable on request—US FDA4 packs
- Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100 mg/20 mL powder for injectable suspensionAvailable on requestMeitheal PharmaceuticalsUS FDA3 packs
- Paclitaxel 100mg per vial 100 mg/20 mL powder for injectable suspensionAvailable on requestExelan PharmaceuticalsUS FDA1 pack
- Paclitaxel Protein Bound Particles Albumin Bound 100 mg/20 mL powder for injectable suspensionAvailable on requestAmerican RegentUS FDA1 pack
Other strengths and forms of Paclitaxel
Clinical summary
Paclitaxel is a microtubule inhibitor indicated for the treatment of metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy, among other approved uses. MedsAcross supplies Paclitaxel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PaclitaxelFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ABRAXANE prescribing information (Abraxis BioScience) · U.S. National Library of Medicine, DailyMed
- Abraxane: European public assessment report (EPAR) · European Medicines Agency
- Apexelsin: European public assessment report (EPAR) · European Medicines Agency
Need Abraxane 100 mg/20 mL powder for injectable suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.